A new global consortium is reshaping how pharmaceutical companies approach AI-powered drug discovery by bringing together multiple specialized AI vendors under one coordinated laboratory partner, rather than forcing sponsors to navigate fragmented point solutions. CellCarta, a contract research organization (CRO) serving the biopharmaceutical industry, announced the launch of its Global Digital Pathology and AI Consortium, designed to accelerate biomarker discovery, patient stratification, and clinical trial execution across oncology, autoimmune, neurodegenerative, and other disease areas.

What's the Real Problem AI Drug Discovery Is Trying to Solve?

The pharmaceutical industry faces a persistent challenge: promising AI concepts often fail to translate into clinically useful evidence. Sponsors struggle to evaluate which AI tools actually work for their specific programs, and they frequently end up cobbling together solutions from multiple vendors, creating operational fragmentation and regulatory uncertainty. The consortium model addresses this by positioning CellCarta as a trusted intermediary that combines traditional laboratory expertise with cutting-edge AI capabilities.

Rather than asking sponsors to choose between competing AI platforms, the consortium remains deliberately "AI-agnostic," meaning it works across multiple technologies and vendors. This flexibility is intentional. As Christopher Ung, Chief Scientific Business Officer of CellCarta, explained the rationale behind the approach.

"AI in pathology is moving quickly, but sponsors do not need another black box or another fragmented vendor pathway. They need a scientifically credible, operationally controlled way to evaluate, validate and deploy the right AI approach for the right program," said Ung.

Christopher Ung, Chief Scientific Business Officer at CellCarta

How Does the Consortium Actually Work for Drug Makers?

The consortium initially brings together seven specialized AI and digital pathology companies, each contributing distinct capabilities to the ecosystem. Rather than forcing sponsors into a one-size-fits-all approach, the model allows pharmaceutical companies to evaluate and deploy the right AI-enabled solution for each specific program.

• Lunit: Provides clinically validated AI solutions for earlier detection and treatment decisions, including immune phenotyping, tumor microenvironment biomarker formation from tissue images, and molecular state prediction.
• Mindpeak: Specializes in turning tissue images and immunohistochemistry data into reproducible, quantitative insights for biomarker discovery and companion diagnostic development.
• Imagene AI: Delivers precision oncology intelligence through multimodal foundation models and proprietary real-world data, accelerating biomarker discovery and patient stratification.
• Dipath AI: A Chinese medical technology company specializing in AI-assisted digital pathology solutions with strong regional presence.
• Nucleai: Applies AI-based image and clinical analysis to drug development, with a track record across antibody-drug conjugate (ADC) clinical programs.
• Tivenix: Expands precision diagnostics reach through AI-enabled bioinformatics and liquid biopsy, leveraging methylation biomarker data for early detection of neurodegenerative conditions.
• Indica Labs: Specializes in AI-powered digital pathology platforms and services supporting discovery, translational research, clinical workflows, and companion diagnostic development.

The consortium's value proposition extends beyond simply providing access to multiple AI companies. Sponsors gain the ability to evaluate, validate, and operationalize these technologies through a global CRO laboratory partner with deep experience in biomarker development, clinical trials, and companion diagnostics. This combination of laboratory infrastructure, pathologist oversight, and regulatory expertise creates a more coherent path forward.

Ehab A. El-Gabry, Chief Medical Officer and Head of Companion Diagnostics at CellCarta, emphasized the shift in how AI should be integrated into drug development.

"Digital pathology and AI are becoming central to the next generation of biomarker development and patient selection. The opportunity is not to replace pathology. It is to make tissue, images and multi-omic data more quantitative, reproducible and actionable," said El-Gabry.

Ehab A. El-Gabry, MD, Chief Medical Officer and Head of Companion Diagnostics at CellCarta

What Specific Problems Does This Solve for Sponsors?

The consortium is designed to support sponsor needs across multiple stages of drug development and discovery. Rather than forcing pharmaceutical companies to navigate vendor fragmentation, the model provides a structured pathway from early-stage exploration to regulatory-ready evidence.

• Exploratory Biomarker Discovery: Sponsors can test multiple AI approaches to identify promising biomarkers without committing to a single vendor or platform.
• Image Analysis and Tumor Characterization: The consortium combines digital pathology expertise with AI-powered image analysis to characterize tumor microenvironments and identify predictive features.
• Patient Stratification and Assay Development: AI tools help identify which patients are most likely to respond to a therapy, enabling more efficient clinical trial design and companion diagnostic strategies.
• Clinical Trial Applications: The consortium supports both retrospective analysis of existing trial data and prospective applications in ongoing studies, with regulatory experience built in.

By combining CellCarta's global histopathology, genomics, immunology, and proteomics capabilities with specialized AI innovators, the consortium aims to reduce the time and uncertainty involved in moving from promising AI signals to clinical-trial-ready evidence. The model is intentionally designed to remain non-exclusive and modular, allowing it to evolve as new technologies mature and additional disease areas emerge.

The consortium represents a broader shift in how the pharmaceutical industry is approaching AI integration. Rather than viewing AI as a standalone tool to be bolted onto existing workflows, leading CROs are positioning AI as a core capability that requires deep integration with laboratory operations, regulatory expertise, and clinical knowledge. This approach acknowledges that the real bottleneck in AI-powered drug discovery is not the availability of AI algorithms, but the ability to validate them, operationalize them, and translate them into regulatory-compliant evidence that sponsors can actually use in their programs.